Botox Must Be Excluded From Medicare Price Negotiation, Judge Rules, Citing Ingredient Made From Human Blood Plasma
A federal judge ruled that Botox should be excluded from Medicare's drug price negotiations as it is derived from human plasma. The decision bars the government from setting a negotiated price for Botox, which would have taken effect in 2028. AbbVie, the drugmaker, argued that Botox contains human serum albumin, a protein from human plasma, and thus qualifies for the exclusion. The ruling does not affect the other 14 drugs in the negotiation round, including Gilead's Biktarvy.
How this was made
The 30-second read
Why it matters
The court's decision prevents a negotiated lower price for Botox, preserving AbbVie's revenue stream from the drug.
Market read
A legal ruling that safeguards pricing for a major revenue driver (Botox) of AbbVie, potentially influencing its stock valuation.
What to watch
Potential for other Part B drugs to face similar legal challenges, altering broader biotech pricing dynamics.
Background
The Inflation Reduction Act allows Medicare to negotiate prices for high‑spending drugs, but excludes plasma‑derived biologics. AbbVie argued Botox falls under this exclusion.
Ticker impact
Federal judge ruled Botox must be excluded from Medicare price negotiations, a decision AbbVie successfully argued, preventing a lower negotiated price.
potential upside as market prices in the blocked price cut
Legal win removes a cost pressure; investors may bid up the stock anticipating better margins.
Market effects
May influence other biotech firms seeking similar exclusions under the IRA.
Limited to U.S. Medicare pricing environment.
Minimal global impact beyond U.S. drug pricing policy.
Counterpoint
If the government appeals and succeeds, a future price cut could hurt AbbVie's margins.
Key entities
- CompanyAbbVie
Pharmaceutical company that manufactures Botox.
- AgencyCMS
Centers for Medicare & Medicaid Services, responsible for price negotiations.
